According to the lawsuits filed in the US District Court for the District of Delaware and the Canadian Federal Court in Toronto, ViiV
alleged Gileads bictegravir of not only violating patent covering dolutegravir but also several other compounds that include the drugs unique chemical scaffold.
said Juluca is the first two-drug regimen comprising dolutegravir 50 mg, an integrase strand transfer inhibitor, and rilpivirine 25 mg, a non-nucleoside reverse transcriptase inhibitor from Janssen Therapeutics.
The study was funded by ViiV
Healthcare and Janssen R&D.
Under the terms of the transactions, ViiV
Healthcare acquired late-stage HIV R/D assets from Bristol-Myers Squibb for an initial upfront payment of USD 317m followed by development and first commercial sale milestones of up to USD 518m, and tiered royalties on sales.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, ViiV
Healthcare Limited's corporate website, SEC filings, investor presentations and featured press releases, both from ViiV
Healthcare Limited and industry-specific third party sources, put together by Global Markets Direct's team.
The media player has received Intel Viiv
technology verification, which tests the compatibility of networked media devices with Intel Viiv
es a las computadoras de escritorio lo que el Centrino es a las computadoras portatiles.
According to the company, Intel Viiv
technology-based entertainment PCs will facilitate downloading, storing, viewing, managing and sharing various digital entertainment and information on a choice of TV, PC, laptop and hand-held viewing screens.
With Gilead and ViiV
Healthcare clearly dominating the HIV market, the remaining companies active in the field have much smaller HIV portfolios.
Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc.
Healthcare, a joint venture of GSK, Pfizer and Shionogi, has started a phase III study with a two-drug regimen of its long-acting, injectable cabotegravir and Janssen Sciences Ireland's long-acting injectable rilpivirine in virally suppressed adults with HIV-1 infection, it was reported yesterday.
have launched a new company called ViiV
Healthcare, which will specialize in treating and meeting the increasingly diverse needs of people worldwide living with HIV/AIDS.